- Home
- XBIO
as of 09-14-2026 4:00pm EST
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immuno-oncology technologies addressing difficult-to-treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors. Its product pipeline consists of two key programs, XBIO-015 and XBIO-020, which are being developed to address pancreatic carcinoma and solid tumours.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | FRAMINGHAM |
| Market Cap: | 6.9M | IPO Year: | 2011 |
| Target Price: | N/A | AVG Volume (30 days): | 33.7K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.60 | EPS Growth: | 38.52 |
| 52 Week Low/High: | $1.90 - $13.93 | Next Earning Date: | 05-13-2026 |
| Revenue: | $2,976,411 | Revenue Growth: | 19.04% |
| Revenue Growth (this year): | 2.81% | Revenue Growth (next year): | -16.67% |
| P/E Ratio: | -6.50 | Index: | N/A |
| Free Cash Flow: | -2286651.0 | FCF Growth: | N/A |
AI-Powered XBIO Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Earnings Transcripts
SEC 8-K filings with transcript text
2026 Q2 Q2 2026 Earnings
8-K BUY Aug 7, 2026 · 100% conf.
Q2 2026 Earnings
8-K BUYAug 7, 2026 · 100% conf.
1D
+4.24%
$3.34
Act: -3.44%
5D
+11.13%
$3.56
Act: +2.50%
20D
+11.29%
$3.56
Transcript text not available. View on SEC.gov →
2026 Q1 Q1 2026 Earnings
8-K May 13, 2026
Q1 2026 Earnings
8-KMay 13, 2026
2025 Q4 Q4 2025 Earnings
8-K Mar 13, 2026
Q4 2025 Earnings
8-KMar 13, 2026
2025 Q3 Q3 2025 Earnings
8-K Nov 13, 2025
Q3 2025 Earnings
8-KNov 13, 2025
2025 Q2 Q2 2025 Earnings
8-K Aug 13, 2025
Q2 2025 Earnings
8-KAug 13, 2025
2025 Q1 Q1 2025 Earnings
8-K May 14, 2025
Q1 2025 Earnings
8-KMay 14, 2025
2024 Q4 Q4 2024 Earnings
8-K Mar 19, 2025
Q4 2024 Earnings
8-KMar 19, 2025
2024 Q3 Q3 2024 Earnings
8-K Nov 13, 2024
Q3 2024 Earnings
8-KNov 13, 2024
2024 Q2 Q2 2024 Earnings
8-K Aug 14, 2024
Q2 2024 Earnings
8-KAug 14, 2024
2024 Q1 Q1 2024 Earnings
8-K May 10, 2024
Q1 2024 Earnings
8-KMay 10, 2024
2023 Q4 Q4 2023 Earnings
8-K Mar 22, 2024
Q4 2023 Earnings
8-KMar 22, 2024
2023 Q3 Q3 2023 Earnings
8-K Nov 13, 2023
Q3 2023 Earnings
8-KNov 13, 2023
2023 Q2 Q2 2023 Earnings
8-K Aug 11, 2023
Q2 2023 Earnings
8-KAug 11, 2023
2023 Q1 Q1 2023 Earnings
8-K May 11, 2023
Q1 2023 Earnings
8-KMay 11, 2023
2022 Q4 Q4 2022 Earnings
8-K Mar 23, 2023
Q4 2022 Earnings
8-KMar 23, 2023
2022 Q3 Q3 2022 Earnings
8-K Nov 10, 2022
Q3 2022 Earnings
8-KNov 10, 2022
2022 Q2 Q2 2022 Earnings
8-K Aug 12, 2022
Q2 2022 Earnings
8-KAug 12, 2022
2021 Q4 Q4 2021 Earnings
8-K Mar 23, 2022
Q4 2021 Earnings
8-KMar 23, 2022
2021 Q3 Q3 2021 Earnings
8-K Nov 12, 2021
Q3 2021 Earnings
8-KNov 12, 2021
2021 Q2 Q2 2021 Earnings
8-K Aug 13, 2021
Q2 2021 Earnings
8-KAug 13, 2021
Compare XBIO vs Leading Stocks
See how XBIO stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "XBIO Xenetic Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.